BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31971933)

  • 1. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.
    Havers FP; Moro PL; Hunter P; Hariri S; Bernstein H
    MMWR Morb Mortal Wkly Rep; 2020 Jan; 69(3):77-83. PubMed ID: 31971933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Liang JL; Tiwari T; Moro P; Messonnier NE; Reingold A; Sawyer M; Clark TA
    MMWR Recomm Rep; 2018 Apr; 67(2):1-44. PubMed ID: 29702631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(1):13-5. PubMed ID: 21228763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(25):468-70. PubMed ID: 22739778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
    MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(41):1424-6. PubMed ID: 22012116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notes from the field : use of tetanus, diphtheria, and pertussis vaccine (Tdap) in an Emergency Department - Arizona, 2009-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jan; 61(3):55-6. PubMed ID: 22278160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
    Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
    J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Feb; 62(7):131-5. PubMed ID: 23425962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetanus and pertussis vaccination coverage among adults aged ≥ 18 years --- United States, 1999 and 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(40):1302-6. PubMed ID: 20948508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2000 Nov; 49(RR-13):1-8. PubMed ID: 11106289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.
    Jackson ML; Yu O; Nelson JC; Nordin JD; Tartof SY; Klein NP; Donahue JG; Irving SA; Glanz JM; McNeil MM; Jackson LA
    Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):921-925. PubMed ID: 29862604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician attitudes and preferences about combined Tdap vaccines for adolescents.
    Davis MM; Broder KR; Cowan AE; Mijalski C; Katrina K; Stokley S; Clark SJ
    Am J Prev Med; 2006 Aug; 31(2):176-80. PubMed ID: 16913066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.